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Summary
Tranexamic acid (TXA) is an antifibrinolytic drug that 
is used for uncontrolled bleeding of various origin. This 
retrospective study investigated the effect of tranexam-
ic acid administration on bleeding tendency in dogs 
with surgically managed hemoperitoneum. Thirty dogs 
were treated with (TXA group) and 25 dogs without 
(CTR group) tranexamic acid prior to surgery. Various 
parameters (decrease in haematocrit, number of trans-
fusions, shock index and changes in abdominal fluid 
accumulation) were used for characterization of bleed-
ing tendency and compared between groups. Groups 
were similar at presentation and prior to surgery. None 
of the dogs undergoing rotational thromboelastography 
analysis showed hyperfibrinolysis prior to surgery. Over-
all transfusion and erythrocyte transfusion require-
ments as well as bleeding tendency, hospitalisation time 
and hospital discharge rate were similar between groups. 
Dogs of the TXA group received significantly more in-
traoperative plasma transfusions (P=0.013) and showed 
a higher systolic and mean arterial blood pressure 
(P=0.002 and 0.050) and lower shock index (P=0.028) 
with less dogs being in shock (P=0.012) at 24h. In sum-
mary, in this study population of dogs with surgically 
managed spontaneous hemoperitoneum dogs treated 
with tranexamic acid received more plasma transfusions 
intraoperatively and showed a lower shock index 24h af-
ter presentation. In dogs with surgically treated hemo-
abdomen tranexamic acid administration prior to sur-
gery does not reduce red blood cell transfusion require-
ments or postoperative bleeding tendency. 
Keywords: canine, hyperfibrinolysis, antifibrinolytic,  
hemoabdomen
Effekt von Tranexamsäure auf  
intra- und postoperative Blutungen  
in  Hunden mit einem chirurgisch  
stabilisierten Hämoperitoneum 
Tranexamsäure ist ein Fibrinolysehemmer, welcher bei 
unkontrollierten Blutungen verschiedener Ursachen 
eingesetzt wird. In dieser retrospektiven Studie wurde 
die Wirkung von Tranexamsäure auf die Blutungsten-
denz von Hunden mit chirurgisch stabilisiertem Hä-
moperitoneum untersucht. Dreissig Hunde wurden mit 
(Gruppe TXA) und 25 ohne Tranexamsäure (Kontrolle) 
behandelt. Verschiedene Parameter (Hämatokritabfall, 
Anzahl Transfusionen, Schockindex, Verlauf von abdo-
minaler Flüssigkeit) wurden als Parameter für die Blu-
tungstendenz zwischen den Gruppen verglichen. Bei 
Präsentation sowie präoperativ waren die Hunde beider 
Gruppen in allen untersuchten Parametern vergleichbar. 
Keiner der untersuchten Hunde zeigte Hyperfibrinolyse 
vor der Operation. Hämatokritabfall, Anzahl Erythro-
zytentransfusionen, Menge an abdominaler Flüssigkeit 
postoperativ, Hospitalisationzeit und Entlassungsrate 
zeigten keinen Unterschied zwischen den zwei Grup-
pen. Die Hunde der Gruppe TXA benötigten intraope-
rativ mehr Plasma-Transfusionen (P-Wert 0.013) und 
zeigten nach der Operation einen signifikant höheren 
systolischen und mittleren Blutdruck (P-Wert 0.002 und 
0.050), einen tieferen Schockindex (P-Wert 0.028) und 
weniger Hunde waren im Schock (P=0.012). Zusam-
mengefasst konnte in dieser Population von Hunden 
mit chirurgisch behandeltem spontanen Hämoabdo-
men kein reduzierter Transfusionsbedarf und keine 
Verminderung der postoperativen Blutungstendenz 
nach Therapie mit Tranexamsäure nachgewiesen wer-
den. Tranexamsäure therapierte Hunde zeigten einen 
niedrigeren Schockindex 24h nach Präsentation und 
bekamen intraoperativ signifikant mehr Plasmatransfu-
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Introduction
Causes for hemoperitoneum include trauma, coagulopa-
thies and rupture of abdominal masses (Clarke et al., 
2002; Nelson and Couto, 2010). Regardless of the cause, 
haemostasis aims at production of a clot to temporarily 
close the endothelial layer. After repair of the vascular 
endothelium, the clot is fibrinolysed (Chapin and 
Hajjar, 2015). With severe haemorrhage, as seen with 
hemoperitoneum, inhibition of fibrinolysis may occur. 
However, hypoperfusion and hypotension can inhibit 
physiological inhibition of fibrinolysis during clot pro-
duction, leading to hyperfibrinolysis (Brohi et al., 2003 
and 2008). While surgically treated abdominal haem-
orrhage should theoretically stop after surgical ligation 
of the bleeding vessel, ongoing fibrinolysis may lead to 
postoperative bleeding tendency (Marin et al., 2012). 
Hyperfibrinolysis can be treated with an antifibrinolyt-
ic such as tranexamic acid (McCormack, 2012). 
Tranexamic acid is a synthetic analogue of lysine. By 
binding to the lysine binding site on plasminogen, bind-
ing of plasmin to fibrinogen and fibrin followed by fi-
brinolysis is prevented (Astedt, 1987). While tranexam-
ic acid is routinely administered to human patients 
including children with severe bleeding (Zufferey et al., 
2006; Schouten et al., 2009; Crash-2 collaborators, 2010; 
Ker et al., 2012; Roberts et al., 2014), only a few studies 
have looked at the effects of antifibrinolytics in dogs 
and have reported conflictive results (Marin et al., 2012; 
Kelmer et al., 2013 and 2015). To the author’s knowl-
edge, no studies investigating the benefit of tranexamic 
acid administration to dogs with surgically controlled 
bleeding exists.
The goal of this retrospective study was to compare 
transfusion requirements and presence of postoperative 
bleeding tendency in dogs treated with and without 
tranexamic acid prior to surgical management of ab-
dominal haemorrhage. The null hypothesis was that 
tranexamic acid administered prior to surgery to dogs 
with hemoabdomen would show no effect on transfu-
sion requirement and signs of postoperative bleeding.
Animals, Material and Methods
The hospital’s databank was searched for dogs that were 
diagnosed with hemoperitoneum between 2010 and 
2016 and undergoing surgical treatment of abdominal 
bleeding. Exclusion criteria included missing data re-
garding bleeding, administration of tranexamic acid 
after induction of anaesthesia and death or euthanasia 
prior to or during surgery. Breed, age, sex and weight, 
clinical signs and laboratory parameters at presentation, 
prior to induction of anaesthesia and 24/48h post oper-
atively, amount and duration of fluid administration, 
diagnosis, transfusion requirements, administration of 
tranexamic acid, duration of hospital stay and hospital 
discharge were extracted from patient records. 
Clinical signs
Recording of clinical signs included heart rate (HR), 
respiratory rate (RR), mucous membrane colour, capil-
lary refill time (CRT) and level of consciousness. Shock 
at presentation was defined as identification of >2 of 
the following: HR > 120/min, pale/white mucous mem-
branes, CRT≥2s and decreased level of consciousness. 
Prior to surgery and at 24h and 48h the shock index (SI) 
was determined by calculating HR/systolic arterial 
blood pressure (Olaussen et al., 2014). A SI > 1.00 was 
considered as haemorrhagic shock (McGowan et al., 
2017). The amount of abdominal fluid was graded as 
none, mild, medium, and severe. Changes in fluid ac-
cumulation over time were defined as “increase” or 
“same/decrease”.
Laboratory parameters
Laboratory parameters from the first 24h were extracted 
as needed for determination of the SPI2 score (King et 
al., 2001) and determination of hypocoagulability. Hy-
pocoagulability was defined as ≥2 coagulation parame-
ters (PT or ExTEM coagulation time (CT), aPTT, fi-
brinogen Clauss concentration or FibTEM maximal clot 
firmness (MCF), and ExTEM MCF or thrombocyte 
count and maximal ExTEM lysis > 15%) indicating 
decreased coagulation. All haematocrit (Hct) measure-
ments over hospitalization time were extracted and the 
lowest and last measured Hct were used for analysis of 
changes over time. Dogs that received red blood cell 
transfusions were excluded from analysis of follow-up 
parameters or changes over time once they received a 
transfusion. For each dog, the number of whole blood, 
packed red blood cells (pRBC) and plasma transfusions 
where recorded for the preoperative, intraoperative and 
postoperative period. For analysis, 450 ml of autotrans-
fusion, 450 ml of fresh whole blood and 1 Unit pf pRBC 
sionen verabreicht was die Interpretation der Resultate 
schwierig macht und keine eindeutige Aussage über den 
Nutzen von Tranexamsäure zulässt. 
Schlüsselwörter: Hund, Hyperfibrinolyse, antifibrinolytisch, 
Hämoabdomen
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were defined as “300 ml erythrocyte transfusion”. One 
unit of plasma was defined as 300 ml of plasma for de-
termination of ml/kg transfusion doses. Postoperative 
haemorrhage (“continuous bleeding”) was defined as ≥1 
of the following: shock index >1.0 at 48h, decrease in 
haematocrit between 24 and 48h, need for erythrocyte 
transfusion post operatively, and increase in abdominal 
fluid accumulation between 24 and 48h. For compari-
son, dogs were assigned to one of the following groups: 
Group TXA received tranexamic acid at least 30 minutes 
prior to surgery while the group CTR was not treated 
with TXA. 
Table 1: Parameters prior to surgery of 30 dogs with surgically treated hemoperitoneum treated with (group TXA) and 25 dogs without  
(group CTR) tranexamic acid.
Group CTR (n=25) Group TXA (n=30)
Parameter n/N Min Max Mean +/– SDmedian n/N Min Max
Mean +/– SD
Median P-value
Age (years) 25/25 3.0 14.7 9.4 ± 3 30/30 4.2 15.3 9.6 ± 3 0.764
Weight (kg) 25/25 10.8 39.5 28 ± 9 30/30 8.4 46.5 26.6 ± 10 0.570
Parameters at presentation
Heart rate (beats/min) 25/25 60 200 132 ± 34 30/30 80 200 137 ± 32 0.552
Respiratory rate (breath/
min)
22/25 20 100 38 30/30 16 100 33 0.436
Temperature (°C) 23/25 35.1 39.9 37.9 ± 1 26/30 35.7 39.6 37.9 ± 1 0.940
Hematocrit (%)) 25/25 19 49
33 ± 8
33
30/30 24 51 31 0.665
Thrombocytes (10*9 /L) 16/25 40 294 107 25/30 16 472 124 0.702
Parameters prior to induction of anaesthesia
Heart rate (beats/min) 25/25 56 200 127 ± 38 30/30 70 200 129 ± 33 0.912
Respiratory rate 
(breaths/min)
24/25 10 160 24 26/30 6 100 24 0.350
Temperature (°C) 24/25 35.7 39.1 27.6 ± 0.8 26/30 36.1 39.7 37.6 ± 0.9 0.875
Systolic blood pressure 
(mmHg)
24/25 60 150 106 ± 26 30/30 65 169 108 ± 24 0.692
MAP (mmHg) 24/25 40 113 71 ± 17 30/30 40 115 75 ± 18 0.418
Lactate (mmol/L) 14/25 1 8 1.89 19/30 1 8 2.5 0.226
Shock index 24/25 0.5 2.8 1.12 30/30 0.68 3.08 1.2 0.964
SPI2 Score 22/25 0.62 0.75 0.73 26/30 0.67 0.75 0.73 0.649
MAP: mean arterial blood pressure, SPI: survival prediction index 
Table 2: Categorical parameters at presentation and prior to induction of anaesthesia in 30 dogs treated with and 25 dogs treated without 
tranexamic acid for surgically managed hemoperitoneum.
Group CTR (n=25) Group TXA (n=30)
Parameter n/N % n/N % P-value
Diagnosis
Malignant neoplasia 13/25 52 23/30 77
0.120
Hemangiosarcoma 11/25 44 18/30 60
Benigne mass 11/25 44 7/30 23
trauma 1/25 4 0/30 0
Amount of abdominal fluid at presentation
None 0 0 0 0
0.399
Mild 10/25 40 8/30 27
Medium 9/25 36 10/30 33
Severe 6/25 24 12 /30 40
Hypocoagulability at presentation Yes 2/5 40 7/17 41 0.684
Hyperfibrinolysis at presentation ML>15% 0/5 0 0/17 0 NA
Presence of shock at presentation yes 16/25 64 20/30 67 0.530
Shock index at induction of anaesthesia >1.00 17/24 71 19/29 66 0.455
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Statistical analysis
Data were entered into a spreadsheet and analyses were 
performed using the statistical software program SPSS. 
The dataset was split into groups TXA and CTR. Dis-
tribution of data was assessed by Shapiro-Wilk and con-
tinuous variables are recorded as mean +/-SD if normal-
ly distributed and median if not normally distributed. 
The frequency distributions of the categorical or ordinal 
(score) variables were derived. Non-normally distributed 
continuous variables were compared with Mann-Whit-
ney-U tests and normally distributed continuous varia-
bles were analysed with t-tests. Associations between 
categorical variables were evaluated using the Chi-
Square test. When both variables were binary and ex-
pected cell frequencies were < 5, Fisher’s test was used. 
Significance was set at P≤ 0.05.
Results
A total of 55 dogs were analysed and included 30 dogs 
(55%) treated with (group TXA) and 25 dogs (45%, 
group CTR) treated without tranexamic acid. Various 
breeds were represented with mixed breeds being the 
most common (17/50, 31%) followed by Retrievers 
(10/55, 18%). Signalement and evaluated parameters at 
presentation and at the time of anaesthesia induction 
were not significantly different between groups (Tab. 1 
and 2). Dogs of the TXA group received a median dose 
of 20 mg/kg (range, 10-25 mg/kg) tranexamic acid at 
least 30 minutes prior to surgery and over a median 
number of 1 day (range, 0.5-2 days) and 1 treatment 
(range, 1-8).
Neither the amount of crystalloid and colloidal fluids 
(P=0.702 and 0.907), administration of erythrocytes 
(P=0.221), postoperative continuous bleeding (P=0.597), 
hospitalization time (P=0.716) nor survival (P=0.412) 
were significantly different between groups (Tab. 3 
and 4). However, dogs of the TXA group showed a sig-
nificantly higher systolic and mean arterial blood pres-
sure (P=0.002 and 0.050) and a lower median shock 
index (P=0.028) with less dogs in shock (P=0.012) 24h 
after surgery (Tab. 3). Furthermore, significantly more 
dogs of the TXA group received plasma transfusions 
during surgery (P=0.013) and less dogs in the TXA group 
underwent splenectomy (P= 0.043) (Tab. 3 and 4). 
Discussion
Our study investigating dogs presenting with surgically 
controlled abdominal haemorrhage did not identify a 
significant difference in intra- or postoperative overall 
transfusion requirements, erythrocyte transfusion re-
quirements or signs of continuous bleeding after surgery. 
Tranexamic acid is used to both prevent bleeding in 
patients undergoing surgeries with high-risk of blood 
loss as well as to decrease bleeding in patients with ex-
istent haemorrhage (Zufferey et al., 2006; Ker et al., 
2012; Napolitano et al., 2013; Lundin et al., 2014; Rob-
erts et al., 2014). The rationale of tranexamic acid ad-
ministration is the occurrence of hypoperfusion-associ-
ated hyperfibrinolysis that may continue after ligation 
of the bleeding vessel. Hypoperfusion and hypotension 
can diminish physiological inhibition of fibrinolysis by 
an increased release of protein C (Brohi et al., 2003 and 
2008). Protein C causes disinhibition of tissue plasmino-
gen activator (tPA) leading to hyperfibrinolysis (Brohi 
et al., 2008). Hyperfibrinolysis has been described in 
dogs with hemoperitoneum (Fletcher et al., 2016; Zoja 
et al., 2017) and has been associated with shock (Fletch-
er et al., 2016). However, the effect of treatment with 
tranexamic acid has not been investigated in dogs with 
hemoperitoneum. Kelmer et al. investigated dogs with 
both primary and secondary haemostasis abnormalities 
and did not find a significant difference in overall trans-
fusion requirement (including plasma) and pRBC trans-
fusion in dogs treated with tranexamic acid if only dogs 
requiring transfusion therapy were included (Kelmer et 
al., 2013). Another study investigating prophylactic ad-
ministration of Epsilon aminocaproic acid, a similar 
antifibrinolytic, to greyhounds undergoing gonadecto-
my showed a significant decrease in the prevalence of 
postoperative bleeding (Marin et al., 2010). None of the 
dogs undergoing rotational thromboelastometry 
 (ROTEM) analysis showed hyperfibrinolysis prior to 
surgery, however only 22/50 dogs were analyzed. On-
going hyperfibrinolysis was not assessed but as the dogs 
in our study population treated with tranexamic acid 
did not need less erythrocyte transfusions and did not 
show decreased incidence of continuous bleeding after 
surgery, hyperfibrinolysis-associated postoperative 
haemorrhage does not seem to dominate in this study 
population. Of note, while the overall transfusion rate 
was not significantly different in our study population, 
analysis of specific blood components showed that dogs 
treated with tranexamic acid received significantly more 
plasma transfusions intraoperatively. Plasma is com-
monly administered for fibrinogen or coagulation factor 
deficiency at our institution. While the detailed reason 
for plasma administration could not be retrospectively 
determined, the assumption that dogs of the TXA group 
had additional coagulation deficiencies and/or plasma 
administration was subject to bias, stands to reason. 
Other causes for continuous bleeding after surgical li-
gation of the bleeding vessel besides hyperfibrinolysis 
may be caused by dilution and loss of coagulation fac-
tors, fibrinogen and thrombocytes (Ledgerwood et al., 
2003). Tranexamic acid has no effect on primary or 
secondary haemostasis (McCormack, 2012). Dogs in 
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Table 3: Continuous postoperative parameters of 30 dogs treated with (group TXA) and 25 dogs without (group CTR) tranexamic acid and surgi-
cally managed hemoperitoneum.
Group CTR (n=25) Group TXA (n=30)
Parameter n/N Min Max Mean +/– SDmedian n/N Min Max
Mean +/– SD
Median P-value
Hematocrit 24h (%) 19/25 17 34 24 ± 5 26/30 12 43 25 0.381
Hematocrit lowest (%) 22/25 10 34 20 ± 7 29/30 12 28 20 ± 5 0.811
Hematocrit last (%)* 13/19 17 40 27 ±7 14/30 21 43 26 0.756
Hematocrit change 24-48h 6/25 –8 8 0.5 6/30 –3 13 2.5 0.553
Hematocrit change from  
presentation to lowest (%)
25/25 –44 3 –15 ± 11 30/30 –33 –3 –14 ± 8 0.793
Hematocrit change from  
presentation to last (%)*
13/25 –21 7 –13 ± 9 14/30 –23 10 –8 ± 8 0.792
Tc day 1 (10*9/L) 8/25 29 238 121 ± 70 13/30 31 230 70 0.374
Tc last (10*9/L) 11/25 72 661 189 20/30 52 1270 156 0.359
HR 24h 24/25 60 180 119 30/30 60 185 95 0.223
Systolic BP 24h 17/25 84 134 110 ± 12 25/30 94 197 133 ±27 0.002
MAP 24h 17/25 67 101 76 ± 10 26/30 53 136 93 ± 22 0.050
Shock index 24h 17/25 0.51 1.67 1.04 ± 0.4 25/30 0.39 1.83 0.73 0.028
HR 48h 23/25 50 150 100 29/30 53 194 84 0.580
Systolic BP 48h 11/25 95 157 122 ± 18 21/30 96 163 125 ± 19 0.584
MAP 48h 11/25 72 100 89 ± 8 22/30 64 111 88 ± 14 0.919
Shock index 48h 11/25 0.42 1.37 0.84 ± 0.3 21/30 0.36 1.88 0.78 ± 0.4 0.618
Erythrocytes intra/post opera-
tively (ml/kg)
25/25 0 28 0 30/30 0 29 3.2 0.296
Plasma intra/post operatively 
(ml/kg)
25/25 0 23.6
2.1 ± 6
0
30/30 0 35
8.4 ± 11
0
0.019
Hospitalisation (days) 25/25 1 10 4 30/30 0 9 4 0.716
Table 4: Categorical postoperative parameters of 30 dogs treated with (group TXA) and 25 dogs without (group CTR) tranexamic acid and  
surgically managed hemoperitoneum.
Group CTR (n=25) Group TXA (n=30)
Parameter n/N % n/N % P-value
Splenectomy yes 23/25 92 21/30 70 0.043
SI at 24h >1.00 10/17 59 5/25 20 0.012
SI at 48h >1.00 4/11 36 5/21 24 0.362
Fluid increase presentation - 24h Yes 1/17 6 1/24 4 0.663
Fluid increase between 24-48h Yes 0/14 0 0/23 0 NA
Continuous bleeding Yes 8/20 40 11/28 39 0.597
Transfusion (pRBC, whole blood or plasma) Yes 9/25 36 17/30 57 0.104
Number of dogs that received 
Erythrocyte transfusions 
Yes 9/25 36 15/30 50 0.221
Intraoperatively 6/25 24 11/30 37 0.237
Postop 3/25 12 7/30 23 0.233
Number of dogs that received
plasma 
Intraoperatively 1/25 4 9/30 30 0.013
Post op 2/25 8 3/30 10 0.588
Hyperfibrinolysis post op ML>15% 1/2 50 0/6 0 0.250
Hospital discharge Yes 22/25 88 28/30 93 0.412
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Effet de l’acide tranexamique sur les 
hémorragies intra- et postopératoires 
chez des chiens traités chirurgicale-
ment pour un hémopéritoine
L’acide tranexamique (TXA) est un médicament anti-
fibrinolytique utilisé lors d’hémorragies incontrôlées 
d’origines diverses. Cette étude rétrospective analyse les 
effets de l’administration d’acide tranexamique sur la 
tendance aux hémorragies sur des chiens souffrant d’un 
hémopéritoine traité chirurgicalement.  Trente chiens 
ont été traités avec de l’acide tranexamique avant chirur-
gie (groupe TXA) et vingt- cinq ne l’ont pas été (groupe 
CTR). Divers paramètres (baisse de l’hématocrite, 
Effetto dell’acido tranexamico sulle 
emorragie intra- e post-operatorie  
nei cani con emoperitoneo trattato 
chirurgicamente 
L’acido tranexamico (TXA) è un farmaco antifibrinoli-
tico usato nei casi di sanguinamento incontrollato di 
varia origine. Questo studio retrospettivo ha esaminato 
l’effetto della somministrazione di acido tranexamico 
sulla tendenza al sanguinamento nei cani con emoperi-
toneo trattato chirurgicamente. Prima dell’intervento 
chirurgico, trenta cani sono stati trattati con l’acido 
tranexamico (gruppo TXA) e 25 senza di esso (gruppo 
CTR). Vari parametri sono stati usati per caratterizzare 
our study were thrombocytopenic both at admission 
and 24h after presentation and the degree of thrombo-
cytopenia was similar in both groups. Furthermore, as 
discussed above, dogs in both groups were similar prior 
to surgery in terms of hypocoagulability based on plas-
matic coagulation times and ROTEM parameters but 
dogs in the TXA group received more intraoperative 
plasma transfusions which does not allow a clear con-
clusion. The increased administration of plasma during 
surgery may also be the reason of the significantly low-
er shock index 24h after presentation in the TXA group. 
The time frame of ongoing haemorrhage may also be 
important and is unknown in spontaneous hemoperito-
neum. The CRASH-2 trial identified the best benefit of 
tranexamic acid if administered within 3 hours of trau-
ma/start of bleeding (Crash-2 investigators, 2010). This 
may be unique to trauma patients as hyperfibrinolysis in 
trauma is seen early after trauma in both humans (Brohi 
et al., 2008; Roberts, 2015) and dogs (Muri et al., accept-
ed 2017). Additionally, it is recommended to repeat ad-
ministration of tranexamic acid every 6-8h if hyperfi-
brinolysis is evident (McCormack, 2012). With less 
evident hyperfibrinolysis, some studies in humans 
showed an effect on postoperative bleeding despite only 
intraoperative administration of tranexamic acid (Tanaka 
et al., 2001; Madershaian et al., 2015). All dogs received 
tranexamic acid 30 minutes to 3 hours prior to surgery 
and an antifibrinolytic effect is expected for the intraop-
erative and early postoperative period (McCormack, 
2012; Kakiuchi et al., 2014). As only a few dogs received 
repeated doses of tranexamic acid we can only conclude 
that a single dose of tranexamic acid prior to surgery was 
not associated with a decrease of transfusion requirement 
and signs of “continuous bleeding”. Hospitalization time 
and survival further was not different between groups, 
indicating that tranexamic acid administration has no 
effect on these parameters in this patient population. 
Main limitations of the study are the small study pop-
ulation and the lack of randomization of tranexamic 
acid administration. However, dogs in both groups were 
comparable at presentation and prior to surgery and 
showed similar SPI2 scores, indicating that despite the 
lack of randomization of tranexamic acid administra-
tion, the TXA group did not receive tranexamic acid 
because of severity of abdominal haemorrhage or clin-
ical presentation. The lack of a clear indication for the 
increased plasma administration intraoperatively pre-
cludes a clear conclusion and the study should therefore 
be interpreted with regards to this finding. Another 
reason for the lack of benefit of tranexamic acid admin-
istration may be the power of the study to detect a sig-
nificant difference. The need for intra- and postopera-
tive red blood cell transfusion was low in both groups. 
It may be possible that haemorrhage was not severe 
enough to cause hyperfibrinolysis, hence no benefit of 
treatment with an antifibrinolytic in this study popula-
tion. The amount of abdominal fluid present at the time 
of surgery could not be retrospectively determined, 
therefore transfusion requirements have been used as 
an outcome as previously described (Ker et al., 2011 and 
2013; Lundin et al., 2014; Madershahian et al., 2015). 
In summary, in this study population of dogs with sur-
gically managed hemoperitoneum, tranexamic acid 
administration prior to surgery did not result in a sig-
nificant decrease in erythrocyte transfusions. Dogs 
treated with tranexamic acid received more plasma 
transfusions intraoperatively and showed a lower shock 
index 24h after presentation. None of the 55 dogs 
showed hyperfibrinolysis at presentation, further ques-
tioning the rationale for tranexamic acid administration 
in dogs with surgically treated hemoabdomen.
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